N@N

INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH), Down By 5.21% ($0.22) From $4.220 After BUYINS.NET Report Predicted Weakness After E

^{Published on 2011-02-25 09:02:38 - WOPRAI}
 

February 24, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, February 16th 2011 stating that INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=isph&id=147506

At the time this story was written, INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) is Down By 5.21% ($0.22) From $4.220 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) - Inspire Pharmaceuticals, Inc., a biopharmaceutical company, focuses on researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective for the treatment of bacterial conjunctivitis; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease. Its product candidates in clinical development include Denufosol tetrasodium for the treatment of cystic fibrosis, which is under phase III clinical trial; Prolacria for the treatment of dry eye disease, which is under phase III clinical trial; AzaSite for the treatment of blepharitis that is under phase II clinical trial; and Glaucoma product candidates, which are in phase I clinical trial. The company has an agreements with Allergan, Inc. to co-promote Elestat in the United States, as well as to develop and commercialize Restasis and Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the United States and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia. Inspire Pharmaceuticals, Inc. was founded in 1993 and is based in Durham, North Carolina.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. INSPIRE PHARMACEUTICALS INC (NASDAQ:ISPH) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net